Found: 39
Select item for more details and to access through your institution.
The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 8, p. 2298, doi. 10.3390/ijms19082298
- By:
- Publication type:
- Article
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 7, p. 3971, doi. 10.1007/s00520-020-05972-2
- By:
- Publication type:
- Article
Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
- Published in:
- Nature Medicine, 2015, v. 21, n. 7, p. 827, doi. 10.1038/nm0715-827b
- By:
- Publication type:
- Article
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
- Published in:
- Nature Medicine, 2015, v. 21, n. 7, p. 795, doi. 10.1038/nm.3870
- By:
- Publication type:
- Article
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 709, doi. 10.1007/s10637-018-0579-8
- By:
- Publication type:
- Article
Prospective Validation of Candidate SNPs of <i>VEGF/VEGFR</i> Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0066774
- By:
- Publication type:
- Article
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5451, doi. 10.3390/cancers15225451
- By:
- Publication type:
- Article
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4683, doi. 10.3390/cancers15194683
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 4974, doi. 10.3390/cancers14204974
- By:
- Publication type:
- Article
Early onset metastatic colorectal cancer in patients receiving panitumumab‐based upfront strategy: Overall and sex‐specific outcomes in the Valentino trial.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 10, p. 1760, doi. 10.1002/ijc.34156
- By:
- Publication type:
- Article
CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
- Published in:
- 2017
- By:
- Publication type:
- journal article
ShorTrip Trial: A Prospective, Multicentric Phase H Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 3, p. 339, doi. 10.1016/j.clcc.2023.06.002
- By:
- Publication type:
- Article
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
- Published in:
- Clinical Colorectal Cancer, 2021, v. 20, n. 4, p. 314, doi. 10.1016/j.clcc.2021.07.001
- By:
- Publication type:
- Article
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
- Published in:
- International Journal of Cancer, 2015, v. 136, n. 1, p. 83, doi. 10.1002/ijc.28955
- By:
- Publication type:
- Article
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
- Published in:
- British Journal of Cancer, 2022, v. 127, n. 5, p. 957, doi. 10.1038/s41416-022-01852-0
- By:
- Publication type:
- Article
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
- Published in:
- 2022
- By:
- Publication type:
- journal article
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 3, p. 449, doi. 10.1038/s41416-021-01591-8
- By:
- Publication type:
- Article
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 3, p. 205, doi. 10.1007/s11523-013-0284-7
- By:
- Publication type:
- Article
FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 302, doi. 10.1002/onco.13642
- By:
- Publication type:
- Article
Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
- Published in:
- Oncologist, 2018, v. 23, n. 10, p. 1178, doi. 10.1634/theoncologist.2017-0573
- By:
- Publication type:
- Article
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2016, v. 21, n. 8, p. 988, doi. 10.1634/theoncologist.2016-0084
- By:
- Publication type:
- Article
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
- Published in:
- Oncologist, 2015, v. 20, n. 11, p. 1261, doi. 10.1634/theoncologist.2015-0171
- By:
- Publication type:
- Article
KRAS and BRAF genotyping of synchronous colorectal carcinomas.
- Published in:
- Oncology Letters, 2014, v. 7, n. 5, p. 1532, doi. 10.3892/ol.2014.1905
- By:
- Publication type:
- Article
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
- Published in:
- 2022
- By:
- Publication type:
- journal article
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 3, p. 1, doi. 10.1093/jnci/dju427
- By:
- Publication type:
- Article
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0193640
- By:
- Publication type:
- Article